MedTrace Logo

Preventing Relapse to Smoking Among Prisoners After Release

NCT04271371 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2024-02-28

No results posted yet for this study

Summary

Prisoners experience huge health inequalities, and their exceptionally high smoking prevalence (five times the national average) contributes significantly to their high mortality. Since the introduction of smoke-free polices across Her Majesty's Prison and Probation Service (HMPPS) in England and Wales, prisoners are now obliged to abstain from smoking while held in prison. This represents a unique opportunity to promote lifelong cessation in this highly disadvantaged and marginalised group. However, evidence suggests most prisoners intend to resume smoking as soon as possible after release. A systematic review of prison smoke-free polices worldwide concluded that there was a need for new research to identify effective strategies to reduce relapse in these individuals.

Conditions

  • Smoking
  • Smoking Reduction
  • Electronic Cigarette Use

Interventions

OTHER

Not yet developed

A prototype intervention will be developed over Phase 1 \& 2 and piloted in Phase 3 of this study.

Sponsors & Collaborators

  • Her Majesty's Prison and Probation Service (HMPPS)

    collaborator UNKNOWN

  • Public Health England

    collaborator OTHER_GOV

  • Cancer Research UK

    collaborator OTHER

  • Plymouth University Peninsula Schools of Medicine & Dentistry (PUPSMD)

    collaborator UNKNOWN

  • University of Nottingham

    lead OTHER

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-08-08
Primary Completion
2023-05-01
Completion
2023-12-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04271371 on ClinicalTrials.gov